FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK) Drug Patent Profile

Which patents cover Famotidine Preservative Free (pharmacy Bulk), and what generic alternatives are available?

Famotidine Preservative Free (pharmacy Bulk) is a drug marketed by Epic Pharma Llc and is included in one NDA.

The generic ingredient in FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK) is famotidine. There are eighteen drug master file entries for this compound. One hundred and forty-six suppliers are listed for this compound. Additional details are available on the famotidine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Famotidine Preservative Free (pharmacy Bulk)

A generic version of FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK) was approved as famotidine by FRESENIUS KABI USA on April 16^th, 2001.

Summary for FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
DailyMed Link:	FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK) at DailyMed

US Patents and Regulatory Information for FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Epic Pharma Llc	FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)	famotidine	INJECTABLE;INJECTION	076322-001	Nov 27, 2002		DISCN	No	No

Market dynamics and financial trajectory for Famotidine Preservative Free (Pharmacy Bulk)

Last updated: February 15, 2026

Market Overview

Famotidine Preservative Free (Pharmacy Bulk) is a formulation primarily used by pharmaceutical manufacturers and compounding pharmacies for creating custom dosages and formulations. It is a preservative-free, bulk version of famotidine, a histamine-2 blocker used primarily in treating gastrointestinal conditions such as ulcers and gastroesophageal reflux disease (GERD). The raw material is supplied in bulk to meet the compounding and manufacturing needs, differing from branded or finished dosage forms.

Key Market Drivers

• Growing prevalence of gastrointestinal disorders: The global incidence of GERD, ulcers, and other acid-related disorders increases demand for famotidine. The Global Burden of Disease Study cites gastrointestinal diseases as a significant health concern.

• Compounding pharmacy expansion: The rise in personalized medicine increases demand for pharmacy bulk supplies. In the U.S., compounding pharmacies account for roughly 3%–4% of prescriptions, with a growing trend driven by regulatory flexibility and patient needs.

• Regulatory and safety considerations: The preservative-free nature reduces potential allergic reactions and safety concerns associated with preservatives such as phenol or benzyl alcohol, making it attractive for specific patient groups and formulations.

• Supply chain and manufacturing constraints: Disruptions in finished dosage form manufacturing temporarily boost demand for bulk raw materials, especially during supply shortages or pandemics.

Market Challenges

• Regulatory restrictions: Stringent FDA guidelines for pharmacy bulk drugs impose quality controls and validation, potentially slowing market growth.

• Pricing and competition: Limited pricing power exists due to regulatory pressures, competitive generics landscape, and the availability of alternative acid reducers like pantoprazole or omeprazole.

• Market saturation: The standard, preservative-containing forms remain widely used, constraining growth in certain regions or markets.

Financial Trajectory

• Historical growth rates: The global pharmaceutical excipients market, which includes pharmacy bulk drugs, has experienced compound annual growth rate (CAGR) of approximately 4%-6% over the past five years. A segment-specific extrapolation suggests famotidine pharmacy bulk supplies could grow around 3%-5% annually, primarily driven by demand in specialized compounding markets.

• Pricing trends: Raw material prices have ranged from $150 to $250 per kilogram in recent years, with minor volatility driven by raw material costs and manufacturing regulation costs.

• Revenue estimates: Based on global market size estimates for pharmacy bulk drugs valued at approximately $2 billion in 2022[1], famotidine bulk supplies comprise a small but increasing share. An estimated incremental revenue of $10–20 million annually is plausible within the next three years for this segment, contingent on growth in compounding pharmacies and regulatory landscape stability.

• Profitability: Margins for raw bulk agents are typically low (5%-15%) due to high competition and regulatory costs. Specialized formulations or high-volume manufacturing could sustain margins at the upper end.

Regional Market Dynamics

• North America: Dominates the market due to high compounding pharmacy utilization, with an estimated CAGR of 4% over the next three years. The market is also influenced by regulatory scrutiny and safety considerations.

• Europe: Similar growth trends, with regulatory harmonization via the European Medicines Agency (EMA) improving market access but caution over compounded drugs.

• Asia-Pacific: Expected to see accelerated growth (5%-7%) driven by expanding healthcare infrastructure and rising prevalence of GI disorders.

Competitive Landscape

• Few large-scale suppliers dominate the pharmacy bulk famotidine market, primarily those integrated with major raw material producers or large pharmaceutical companies.

• Entry barriers include strict compliance, validation requirements, and entrenched relationships with compounding pharmacies.

Regulatory Environment

• The U.S. FDA classifies pharmacy bulk drugs under 21 CFR 210 and 211, requiring rigorous testing for purity, stability, and safety.

• Pharmacies must adhere to USP <797> guidelines and Good Manufacturing Practices (GMP), influencing market entry and product development.

Conclusion

Demand for Famotidine Preservative Free (Pharmacy Bulk) is driven by the growth of compounding pharmacies, increasing gastrointestinal disorder prevalence, and safety considerations. While regulatory hurdles and pricing pressures temper rapid growth, stable and moderate expansion is anticipated within a 3%-5% CAGR over the next three years.

---

Key Takeaways

• The market remains niche with growth aligned to compounding pharmacy trends.
• Regulatory complexity influences supply and pricing.
• Regional variation impacts growth potential, with North America leading.
• Pricing and margins are modest, with profitability tied to volume.
• Industry consolidation and capacity investments could shift competitive dynamics.

---

FAQs

1. What is the main use of famotidine preservative-free bulk?
   It serves as raw material for compounding pharmacies and manufacturers creating customized formulations for gastrointestinal treatments.

2. How does regulation affect its market?
   Strict FDA and USP regulations require extensive testing and validation, increasing costs and potentially restricting market entry.

3. What are the recent trends impacting the demand?
   Growing GI disorders, the rise in personalized medicine, and safety concerns about preservatives bolster demand in specific markets.

4. What factors could accelerate market growth?
   Regulatory relaxations, technological advances reducing production costs, and increasing acceptance of compounded medications.

5. Who are the primary market players?
   Currently, a limited number of suppliers dominate, including large pharmaceutical and raw material producers, though new entrants face significant barriers.

---

Citations

[1] IQVIA, “Global Pharmaceuticals Market Report,” 2022.